DYNAMOS
Other Neurological Disorders
GRIN Therapeutics, Inc.Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Other Neurological Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rosuvastatin GRIN Therapeutics, Inc. | Phase 1 | CC |
WARFARIN GRIN Therapeutics, Inc. | Phase 1 | CC |
Omeprazole GRIN Therapeutics, Inc. | Phase 1 | CC |
PHYTONADIONE, (E)-(±)- GRIN Therapeutics, Inc. | Phase 1 | CC |
Radiprodil GRIN Therapeutics, Inc. | Phase 1 | CC |
Itraconazole GRIN Therapeutics, Inc. | Phase 1 | CC |
Carbamazepine GRIN Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
DYNAMOS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →